Compare · NVO vs TTRX
NVO vs TTRX
Side-by-side comparison of Novo Nordisk A/S (NVO) and Turn Therapeutics Inc. (TTRX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and TTRX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $183.82B, about 1740.8x TTRX ($105.6M).
- Over the past year, NVO is down 34.2% and TTRX is down 52.2% - NVO leads by 17.9 points.
- NVO has hit the wire 5 times in the past 4 weeks while TTRX has been quiet.
- NVO has more recent analyst coverage (25 ratings vs 1 for TTRX).
- Company
- Novo Nordisk A/S
- Turn Therapeutics Inc.
- Price
- $41.18+6.93%
- $3.48+4.82%
- Market cap
- $183.82B
- $105.6M
- 1M return
- +13.32%
- +2.35%
- 1Y return
- -34.24%
- -52.16%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 5
- 0
- Recent ratings
- 25
- 1
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NVO
- The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Wolfe Research initiated coverage on Novo Nordisk A/S
Latest TTRX
- SEC Form 4 filed by Burnam Bradley Evan
- SEC Form 4 filed by Golden Arthur F
- SEC Form 4 filed by Burnam Bradley Evan
- SEC Form 4 filed by Chaudhary Zuraiz
- SEC Form EFFECT filed by Turn Therapeutics Inc.
- SEC Form EFFECT filed by Turn Therapeutics Inc.
- SEC Form POS AM filed by Turn Therapeutics Inc.
- SEC Form POS AM filed by Turn Therapeutics Inc.
- SEC Form 10-K filed by Turn Therapeutics Inc.
- Turn Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition